 Autolus Therapeutics plc AUTL, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced preclinical data related to AUTO5 in T cell lymphoma and AUTO6NG in small cell lung cancer, as well as an oral presentation related to AUTO7 in prostate cancer at the American Association for Cancer Research AACR Virtual Annual Meeting II on June 22 - 24, 2020. Behind our lead programs AUTO1 in ALL and AUTO3 in DLBCL, we have a number of exciting preclinical product candidates progressing towards the clinic, said Dr Christian Itin, chairman and chief executive officer of Autolus. 